Skip to main content

UPDATE 1-Spring Bank stops hepatitis drug development after patient dies during trial

Shares of Spring Bank Pharmaceuticals plummeted 26% on Wednesday after the company said it would end the development of an experimental drug to treat chronic hepatitis B virus, following the death of a patient in a mid-stage trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.